Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dycal is a rigid-setting, self-curing, radiopaque calcium hydroxide composition used primarily in dentistry as a cavity liner and for direct and indirect pulp capping. It acts as a protective barrier under restorative materials such as adhesives, varnishes, filling materials, cements, and other base materials. The main mechanism of action is the stimulation of secondary dentin formation by providing an alkaline environment that encourages odontoblast activity while protecting the dental pulp from chemical irritation. It is biocompatible but can be cytotoxic to certain cell types in vitro; however, it has a long record of clinical success for vital pulp therapy. The product does not inhibit the polymerization of acrylic or composite restorations and offers quick setting times with good handling characteristics[1][2][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dycal.